Article citationsMore>>

Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. and Stilgenbauer, S. (2010) Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukaemia: A Randomised, Open-Label, Phase 3 Trial. The Lancet, 376, 1164-1174.
https://doi.org/10.1016/S0140-6736(10)61381-5

has been cited by the following article:

• TITLE: A Rare Entity of Accelerated Chronic Lymphocytic Leukemia: A Report of Two Cases and Review of Literature

  AUTHORS: Zahra Kmira, Ben Yahya Noura, Chembah Wafa, Ben Sayed Nesrine, Chiba Dorra, Bouteraa Walid, Zaier Monia, Ben Youssef Yosra, Haifa Regaieg, Khelif Abderrahim

  KEYWORDS: Accelerated Chronic Lymphocytic Leukemia, Richter Transformation, Prognosis, Treatment

  JOURNAL NAME: Health, Vol.15 No.8, August 22, 2023

  ABSTRACT: Background: Accelerated-chronic lymphocytic leukemia (A-CLL) is a rare disease entity as it represents less than 1% of all reported cases of chronic lymphoid leukemia (CLL). Moreover, it is most likely an under diagnosed entity due to its rarity and the non-standardized practice of lymph node biopsy in CLL. Purpose: The aims of our work are to establish the diagnosis of A-CLL and to study the prognosis and treatment of this rare entity. Method: here, we report the clinical presentation and the follow up of two cases of A-CLL. Results: Distinguishing Richter transformation (RT) from A-CLL is important as it may result in a major change in disease management. The prognosis of A-CLL is intermediate between CLL and RT. The prognosis is mainly poor due to a predominance of poor prognostic markers including an increasing number of p53-positive cases. Conclusion: To this date, no prospective study has been led to define the best treatment for A-CLL. The shorter survival of A-CLL when compared to typical CLL implies the need of a more aggressive treatment.